Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial

BACKGROUND: Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG) is an unexplored therapy amidst the rapidly evolving spectrum of medical therapies for COVID-19 and is expected to counter the three most life-threatening consequences of COVID-19 including lung injury by the virus, cytokine s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:EClinicalMedicine
Autores principales: Ali, Shaukat, Uddin, Syed Muneeb, Shalim, Elisha, Sayeed, Muneeba Ahsan, Anjum, Fatima, Saleem, Farah, Muhaymin, Sheikh Muhammad, Ali, Ayesha, Ali, Mir Rashid, Ahmed, Iqra, Mushtaq, Tehreem, Khan, Sadaf, Shahab, Faisal, Luxmi, Shobha, Kumar, Suneel, Arain, Habiba, Khan, Mujtaba, Khan, Abdul Samad, Mehmood, Hamid, Rasheed, Abdur, Jahangeer, Ashraf, Baig, SaifUllah, Quraishy, Saeed
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177439/
https://ncbi.nlm.nih.gov/pubmed/34109306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100926
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares